Agents for Change: The 10th Invest in ME International ME Conference, 2015 - Part 1
The 10th Invest in ME International ME Conference (IIMEC10) was held, as usual, in the Lecture Theatre at 1 Birdcage Walk in Westminster on May 29th, 2015.
Discuss the article on the Forums.

FDA OKs Northera for Hypotension

Discussion in 'General ME/CFS News' started by Ema, Feb 19, 2014.

  1. Ema

    Ema Senior Member

    Midwest USA
    The FDA has approved droxidopa (Northera) for the treatment of neurogenic orthostatic hypotension, a rare disease that results in a drop in blood pressure when patients try to stand up.

    The drug was passed up for approval 2 years ago when the FDA asked for more data from an additional clinical trial.

    Approval stems from two clinical trials, each 2 weeks long, in which patients on droxidopa reported less dizziness, lightheadedness, feeling faint, or feeling as if they might black out than those on placebo.

    The FDA noted, however, that the drug was OK'd under its accelerated approval program, which allows it to go on-market for demonstrating an effect on an "intermediate clinical measure" -- in this case, short-term relief of dizziness.
    Valentijn likes this.

See more popular forum discussions.

Share This Page